BrightSpring Health Services, Inc. (BTSG) · Oct 30, 2026 · Earnings
Beat — Adjusted EPS $0.54 vs ~$0.45 consensus
BrightSpring earnings beat Q3 revenue expectations by a wide margin, while higher 2026 revenue and EBITDA guidance reinforces its growth story.
BrightSpring is operating as a continuing-operations platform combining specialty pharmacy with home-health and other provider services, while using the Amedisys and LHC branch acquisition to expand its care footprint. The Community Living divestiture has simplified the story toward those two growth engines.
The quarter cleared expectations by a wide margin. Revenue reached $4.213 billion versus a published consensus of roughly $3.88 billion, an approximately 8.6% beat; adjusted EPS was $0.54 versus about $0.45 expected. The filing also shows diluted continuing-operations EPS of $0.46, up from $0.17 a year earlier.
| Metric | Q3 2026 | Q3 2025 | Consensus |
|---|---|---|---|
| Revenue (Financial Highlights) | $4.213B (+26.4%) | $3.334B | ~$3.88B |
| Adjusted EPS (Adjusted EPS reconciliation) | $0.54 | $0.30 | ~$0.45 |
| Adjusted EBITDA (Financial Highlights) | $227.8M (+42.0%) | $160.4M | |
| Diluted EPS, continuing operations (Income Statement) | $0.46 | $0.17 |
Growth was broad, but pharmacy remains the main engine. Pharmacy Solutions revenue rose 26% and segment EBITDA increased 43%, while Provider Services revenue grew 31% and segment EBITDA rose 30%. Prescription volume was nearly flat, so the pharmacy result was driven more by revenue and gross profit per script than by dispensing volume.
Management raised the full-year bar rather than merely repeating it. 2026 revenue guidance now stands at $15.9 billion to $16.125 billion, with adjusted EBITDA at $850 million to $860 million; the filing does not provide the prior ranges, so the size of the increase cannot be quantified here. The Amedisys and LHC branches acquisition is expected to contribute about $35 million of 2026 adjusted EBITDA, making the acquired footprint part of the outlook but not the whole explanation for the beat. 〔0〕
The balance sheet also gives the raised outlook more support. Leverage fell to 1.79x from 2.15x at June 30, while nine-month operating cash flow reached $371.2 million and debt declined by roughly $325 million from year-end. That improves financial flexibility as BrightSpring continues investing in provider growth, although the filing still identifies substantial indebtedness and reimbursement pressure as ongoing business risks.
Bottom line: This is more than a routine in-line quarter: BrightSpring delivered a clear earnings and revenue beat, raised its 2026 targets, and showed stronger cash generation and lower leverage. The event materially strengthens the growth-and-execution story heading into 2027.
Q4 earnings and initial 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!